Ingrezza (Valbenazine)

Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of TD. VMAT2 has been identified as a pharmacological target for hyperkinetic movement disorders; Ingrezza causes reversible reduction of dopamine release by selectively inhibiting...